Beyond mismatch repair in colorectal cancer liver metastases: rethinking immunotherapy through the hepatic metastatic niche - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reevaluating Immunotherapy in Colorectal Cancer Liver Metastases: The Role of the Hepatic Metastatic Microenvironment Beyond Mismatch Repair

  • By

  • Lei Yang

  • Yuehua Liang

  • Wenqiang Wang

  • Jingjing Li

  • Bo Jia

  • Min Fu

  • Xialin Xie

  • Qian Chen

  • September 7, 2026

Share

  • 1

    dMMR/MSI-H status is the primary biomarker for immunotherapy in metastatic colorectal cancer, showing durable benefits with pembrolizumab.

  • 2

    Active hepatic disease is linked to poorer outcomes in checkpoint therapy, but findings are inconsistent and do not warrant withholding treatment.

  • 3

    Clinical data indicate that liver metastases correlate with reduced disease control and diminished benefits from checkpoint inhibitors.

  • 4

    The liver's immunologically active environment may deplete tumor-specific T cells and impair T-cell activation, affecting immunotherapy efficacy.

  • 5

    Active colorectal liver metastases may act as treatment-effect modifiers rather than established predictive biomarkers for immunotherapy.

Original Source(s)

Beyond mismatch repair in colorectal cancer liver metastases: rethinking immunotherapy through the hepatic metastatic niche

  • by Lei Yang, Yuehua Liang, Wenqiang Wang, Jingjing Li, Bo Jia, Min Fu, Xialin Xie, Qian Chen

  • September 7, 2026

Related Content

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Therapy-induced immunoediting and the evolution of cancer immune escape

Physical exercise in brain tumor patients: a systematic review